Source: MarketScreener

Catalyst Pharmaceuticals: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

(marketscreener.com) NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Catalyst Pharmaceuticals, Inc. ("Catalyst" or the "Company") (NASDAQ: CPRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The...http://www.marketscreener.com/news/Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Catalyst-Pharmaceuticals-Inc-C--29499126/?utm_medium=RSS&utm_content=20191101

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Catalyst Pharmaceuticals's latest SEC filings

Annual Revenue

Based on data from Catalyst Pharmaceuticals's latest SEC filings

Employees

Patrick J. McEnany's photo - Chairman & CEO of Catalyst Pharmaceuticals

Chairman & CEO

Patrick J. McEnany

CEO Approval Rating

72/100

Catalyst is a specialty pharmaceutical company focused on in-licensing and developing.

Catalyst Pharmaceuticals's headqua...
Read more